EPIRUS Biopharmaceuticals Inc - ESG Rating & Company Profile powered by AI
The Disclosure score includes seventeen United Nations Sustainable Development Goals including: 'Clean Water & Sanitation', 'Sustainable Cities & Communities' and 'Life on Land'. Scroll down to the bottom of the page for potential risks for EPIRUS Biopharmaceuticals Inc based on sector, geography and size. The page contains a Q&A table for EPIRUS Biopharmaceuticals Inc.
EPIRUS Biopharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 2747 | Aphria Inc | 0.3 | Low |
| 2747 | Sichuan Languang Development Co Ltd | 0.3 | Low |
| 2749 | EPIRUS Biopharmaceuticals Inc | 0.0 | Low |
| 2749 | Alpha Group Industries Inc | 0.0 | Low |
| 2749 | BNC Korea Co Ltd (Pre-Merger) | 0.0 | Low |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does EPIRUS Biopharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid EPIRUS Biopharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas EPIRUS Biopharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs EPIRUS Biopharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes EPIRUS Biopharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes EPIRUS Biopharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for EPIRUS Biopharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.